Symptoms of multiple sclerosis are generally the same, regardless of how old you are when it develops. The differences lie in which symptoms you're more likely to have and how quickly they get worse.

Generally, evidence notes that hypersexuality with multiple sclerosis (MS) is uncommon. A 2024 review investigating hypersexuality in neurological disorders wanted to include MS, but did not as ...

Many MS Awareness Month events take place during March. If you live with or know someone with MS, you can show your support by wearing orange, participating in events, and educating yourself about ...

Aug. 23, 2024 — A collaborative investigation among experts in Alzheimer's disease and multiple sclerosis (MS) finds evidence that MS patients are less likely to have amyloid plaques ...

Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the protective myelin sheaths that surround nerve fibres, leading to neurological disturbances. The mechanisms ...

Opens in a new tab or window Intermittent calorie restriction lowered leptin levels in a small trial of relapsing-remitting multiple sclerosis (MS). Leptin may have a pathogenic role in MS ...

"These experiments reveal a key underlying mechanism for the loss of immune regulation in MS and likely other autoimmune diseases," said Hafler, who is also chair of Yale's Department of Neurology.

"These experiments reveal a key underlying mechanism for the loss of immune regulation in MS and likely other autoimmune diseases," said Hafler, who is also chair of Yale's Department of Neurology.

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

Since revealing she was diagnosed with multiple sclerosis (MS) in 2021, Christina Applegate has been candid about her health and how's she's doing. She recently passed the three-year anniversary ...

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease ...

“These experiments reveal a key underlying mechanism for the loss of immune regulation in MS and likely other autoimmune diseases,” said Hafler, who is also chair of Yale’s Department of Neurology.